Beijing Yongtai Ruike Biotechnology Company Ltd

Quick facts

Phase 2 pipeline

• CAR-T-19 cell injection · Oncology
  CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Beijing Yongtai Ruike Biotechnology Company Ltd portfolio CI brief
• Beijing Yongtai Ruike Biotechnology Company Ltd pipeline updates RSS

Related

• Sector hub: All tracked pharma companies